Sanofi Scores Clinical Win In Sixth Disease For Dupixent
First Biologic To Reduce Itch And Skin Lesions From Prurigo Nodularis
The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.
You may also be interested in...
As the American Academy of Dermatology meeting ends in Boston, Scrip looks at some of the key data presented at the congress covering the latest advances in the hot area of atopic dermatitis, alopecia and butterfly skin.
The French major has hit a rare roadblock in the onward march of its anti-inflammatory blockbuster.
CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."